Pomerantz LLP Opens Securities Fraud Investigation Into Rafael Holdings After 34.98% Stock Drop

Pomerantz LLP is investigating securities fraud claims on behalf of investors of Rafael Holdings, Inc. (NYSE: RFL), the firm said in a November 3, 2026 announcement. The FinancialContent Business Page published the alert. The investigation concerns whether Rafael Holdings and certain of its officers or directors engaged in securities fraud or other unlawful business practices.

Pomerantz's Rafael Holdings Investigation

Pomerantz LLP is a plaintiff-side securities litigation law firm founded in 1936 that represents investors in securities class actions, corporate governance cases and global investor recovery proceedings, according to akta.pro company records. The firm directs Rafael Holdings investors to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

The investigation follows Rafael Holdings' September 30, 2026 press release announcing topline efficacy and safety data from its Cyclo Therapeutics, LLC subsidiary's pivotal Phase 3 TransportNPC study (CTD-TCNPC-301). The study evaluated Trappsol Cyclo (intravenous hydroxypropyl-β-cyclodextrin) in 94 patients diagnosed with Niemann-Pick Disease Type C. The press release said the result did not achieve statistical significance on the primary endpoint.

Rafael Holdings' stock price fell $0.71 per share, or 34.98%, to close at $1.32 per share on September 30, 2026. On October 29, 2026, Rafael Holdings submitted an NDA to the FDA for remibetadex (Trappsol Cyclo) to treat Niemann-Pick Disease Type C, Stock Titan reported. The Phase 3 study missed its primary endpoint but showed a 64% relative slowing of disease progression versus placebo, with serious adverse events more frequent.

Pomerantz's Litigation Track Record

Pomerantz LLP maintains a global network of offices across New York, Chicago, Los Angeles, London, Paris and Tel Aviv, according to company records. The firm's historic recoveries include $3 billion for investors in the Petrobras securities litigation, $350 million for United Healthcare investors and $225 million for Comverse Technology investors.

Earlier Pomerantz Investor Alerts

Pomerantz LLP announced a proposed class action settlement for purchasers of Gritstone bio securities on September 28, 2026, with a hearing set for December 4, 2026 and a $6 million settlement fund, PR Newswire reported. On September 1, 2026, the firm announced a class action lawsuit against Taboola.com Ltd. over alleged securities fraud, FinancialContent Business Page reported. Pomerantz announced on August 25, 2026 that a class action lawsuit had been filed against GPGI, Inc. alleging securities fraud or unlawful business practices, FinancialContent Business Page reported.

Rafael Holdings' Conference Appearance

Rafael Holdings will host a fireside chat and one-on-one investor meetings at the Guggenheim 3rd Annual Healthcare Innovation Conference in Boston on November 9, 2026, Stock Titan reported.